SEC Form 4 · accession 0001562180-17-003956
ARRAY BIOPHARMA INC · ARRY
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Nicholas A Saccomano
Officer — CSO
Period of report
Dec 16, 2017
Accepted (ET)
Dec 19, 2017 · 9:05 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001100412
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Dec 16, 2017 | M | 5,468 | $0.00 | A | 57,069 | D | |
| Common StockF3 | Dec 16, 2017 | F | 2,548 | $10.92 | D | 54,521 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitsF5,F4 | $0.00 | Dec 16, 2017 | M | 5,468 | D | — | Dec 16, 2020 | Common Stock | 5,468 | 16,407 | D |
| Restricted Stock UnitsF6 | $0.00 | Dec 16, 2017 | A | 28,000 | A | — | Dec 17, 2021 | Common Stock | 28,000 | 28,000 | D |
| Stock Option (Right to Buy)F7 | $10.92 | Dec 16, 2017 | A | 168,000 | A | — | Dec 16, 2027 | Common Stock | 168,000 | 168,000 | D |
Explanation of responses
- F1Shares issued upon settlement of Restricted Stock Units ("RSUs") granted by the Issuer on December 27, 2016 as a result of the vesting of one fourth of such RSUs.
- F2Includes 13,750 unvested RSUs awarded on April 1, 2015 to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Array BioPharma Inc. common stock and which were reported by the reporting person on Table I on a form 4 filed upon grant of the RSUs.
- F3Represents shares withheld to satisfy tax withholding obligations of the reporting person.
- F4The RSUs vested on December 16, 2017.
- F5Consists of remaining unvested RSUs awarded to the reporting person for no additional cash consideration on December 16, 2016, which vest in three equal remaining installments beginning December 16, 2018, and represent a contingent right to receive one share of Array BioPharma Inc. common stock. The grant of these RSUs were previously reported on a Table II of a form 4 filed by the reporting person.
- F6Consists of RSUs awarded to the reporting person for no additional cash consideration each of which represent a contingent right to receive one share of Array BioPharma Inc. common stock. The RSUs vest and will be settled in stock in four equal annual installments beginning on December 16, 2018.
- F7The option vests in four equal annual installments beginning on December 16, 2018.